Dr. Benjamin Jacobs, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Pittsburgh School of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 669
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: University of Pittsburgh School of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
PA license MD443557 · PA license MT196037 -
Hematology & Oncology Physician
PA license MD443557
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Chester County Hospital West Chester, PA
- Main Line Hospital Lankenau Wynnewood, PA
- Bryn Mawr Hospital Bryn Mawr, PA
- Riddle Memorial Hospital Media, PA
Medical groups
- Alliance Cancer Specialists P.c. (43 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 669
- Services billed
- 230,329
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 18,800 | 13 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 13,080 | 17 |
| Injection, denosumab, 1 mg | 7,860 | 29 |
| Injection, fosaprepitant, 1 mg | 5,100 | 19 |
| Injection, ferric derisomaltose, 10 mg | 3,300 | 29 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,037 | 334 |
| Injection, palonosetron hcl, 25 mcg | 920 | 33 |
| Injection, dexamethasone sodium phosphate, 1 mg | 870 | 34 |
| Insertion of needle into vein for collection of blood sample | 841 | 311 |
| Established patient office or other outpatient visit, 30-39 minutes | 605 | 246 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone Hcl Other prescribers in Media, PA | 96 |
| Anastrozole Other prescribers in Media, PA | 72 |
| Calquence (acalabrutinib maleate) | 43 |
| Hydroxyurea Other prescribers in Media, PA | 40 |
| Eliquis (apixaban) Other prescribers in Media, PA | 38 |
| Ondansetron Odt (ondansetron) Other prescribers in Media, PA | 38 |
| Prednisone Other prescribers in Media, PA | 31 |
| Potassium Chloride Other prescribers in Media, PA | 24 |
| Revlimid (lenalidomide) | 24 |
| Letrozole Other prescribers in Media, PA | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 32 companies reported 144 payments worth $3,189 in total to this clinician.
| Food and Beverage | $3,189 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $63,157 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or…
Amgen Inc. - Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics, Inc. · Active, not recruiting · NCT03785249 - RAMP 203
Verastem, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.